...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cytokine >Tumor inherent interferons: Impact on immune reactivity and immunotherapy
【24h】

Tumor inherent interferons: Impact on immune reactivity and immunotherapy

机译：肿瘤固有的干扰素：对免疫反应性和免疫疗法的影响

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Immunotherapy has revolutionized cancer treatment, with sustained responses to immune checkpoint inhibitors reported in a number of malignancies. Such therapeutics are now being trialed in aggressive or advanced cancers that are heavily reliant on untargeted therapies, such as triple negative breast cancer. However, responses have been underwhelming to date and are very difficult to predict, leading to an inability to accurately weigh up the benefit-to-risk ratio for their implementation. The tumor immune microenvironment has been closely linked to immunotherapeutic response, with superior responses observed in patients with T cell-inflamed or 'hot' tumors. One class of cytokines, the type I interferons, are a major dictator of tumor immune infiltration and activation. Tumor cell inherent interferon signaling dramatically influences the immune microenvironment and the expression of immune checkpoint proteins, hence regulators and targets of this pathway are candidate biomarkers of immunotherapeutic response. In support of a link between IFN signaling and immunotherapeutic response, the combination of type I interferon inducers with checkpoint immunotherapy has recently been demonstrated critical for a sustained anti-tumor response in aggressive breast cancer models. Here we review evidence that links type I interferons with a hot tumor immune microenvironment, response to checkpoint inhibitors and reduced risk of metastasis that supports their use as biomarkers and therapeutics in oncology.
机译：免疫疗法已彻底改变癌症治疗，对一些恶性肿瘤报告的免疫检查点抑制剂的持续反应。这种治疗剂现在正在侵略性或晚期癌症中试验，这些癌症严重依赖于未标准的疗法，例如三重阴性乳腺癌。然而，迄今为止的反应是迄今为止的，并且非常难以预测，导致无法准确地对其实施的福利对风险率进行准巧。肿瘤免疫微环境与免疫治疗反应密切相关，具有在T细胞发炎或“热”肿瘤的患者中观察到的优异反应。一类细胞因子，I型干扰素，是肿瘤免疫浸润和活化的主要独裁者。肿瘤细胞固有的干扰素信号传导显着影响免疫微环境和免疫检查点蛋白的表达，因此调节剂和该途径的靶标是免疫治疗反应的候选生物标志物。为了支持IFN信号传导和免疫治疗反应之间的联系，最近已经证明了具有检查点免疫疗法的I型干扰素诱导剂的组合对于侵袭性乳腺癌模型中的持续抗肿瘤反应至关重要。在这里，我们审查了将I型干扰素与热肿瘤免疫微环境联系起来的证据，响应检查点抑制剂，降低转移的风险降低，支持其用作肿瘤学中的生物标志物和治疗剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号